Skip to main content
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
How Care Works
Virtual & Home Visits
Virtual care across 40 states + house calls in Philadelphia
Concierge vs. Direct Care
Zero visit copays, zero hidden fees, relationship model
Send Medical Records
Securely upload prior labs & notes before consultation
Common Questions (FAQ)
PCP scope, insurance, labs & cancellation policies
Services
Primary Care & Acute Visits
Same-day sick visits, refills & comprehensive PCP care
Chronic & Complex Care
POTS, MCAS, Long COVID, Lyme & fatigue workups
Hormones & Endocrine
TRT, thyroid, perimenopause, menopause & PCOS
Metabolic Health & Weight
Advanced lipid testing, GLP-1s & glucose monitoring
Longevity & Prevention
Medicine 3.0 baselines, VO2 max, DEXA & prevention
All Clinical Services
Comprehensive catalogue of 36+ clinical services
Membership
Membership Details
Unlimited direct access, continuous physician care
Care Packages
The Reset & Strategic Roadmap evaluations
Billing & Payment FAQ
HSA/FSA eligibility, transparent cancellation policy
About
Meet Dr. Ash
Your Physician
GER·O·SPAN
Our Clinical Framework
Clinical Library & Articles
Evidence-based health guides reviewed by Dr. Ash
What People Say
124 patient reviews across 6 platforms
Contact Dr. Ash
Reach out with questions or book an intro
Patient PortalStart Intake
Cleerly CTA vs. Standard Coronary CT Angiography (CCTA): Clinical Guide
Fishtown Medicine•11 min read
4.96 (124)

Cleerly AI vs. Standard Coronary CT Angiography (CCTA)

Why a zero calcium score misses soft plaque under age 55 - and how to decide between a $450 radiologist-read CCTA and a $2,000 AI plaque volume report.

Ashvin Vijayakumar MD

Medically Reviewed

Ashvin Vijayakumar MD•Updated October 17, 2026
On This Page
  • TL;DR - The Plain-Language Summary
  • Why Does a Calcium Score of Zero (CAC = 0) Miss Soft Plaque in Younger Adults?
  • Does Cleerly AI Improve Heart Outcomes Over a Standard $450 CCTA?
  • 1. Standard CCTA has 10-year randomized trial proof (SCOT-HEART)
  • 2. What AI quantitative plaque overlays (Cleerly / AI-QCT) add - and where the evidence stops
  • What Is the Cost and Radiation Ladder for Heart Scans in Philadelphia?
  • Two radiation tips that cut your dose in half
  • Who Should Avoid a CCTA (or Use a Different Test)?
  • Your Monday-Morning Heart Imaging Protocol (If -> Then Rules)
  • Common Questions
  • What is the difference between a standard CCTA and a Cleerly CTA?
  • Can you have blocked arteries or soft plaque with a Calcium Score of 0?
  • Does Cleerly AI have randomized trial proof that it prevents more heart attacks than a standard CCTA?
  • How much radiation is in a CCTA or Cleerly scan?
  • Can soft plaque shrink (regress) once you find it on a CCTA?
  • Deep Questions
  • What are the four "high-risk plaque" (HRP) features on a CCTA, and how much do they raise heart attack risk?
  • How does CAD-RADS 2.0 grading on a standard CCTA compare to AI plaque staging?
  • What is the difference between Cleerly (AI-QCT) and HeartFlow (FFR-CT)?
  • Why does Fishtown Medicine pass through imaging discounts with zero markup?
  • Scientific References

Get a preventive doctor that knows you.

Consult Dr. Ash
TL;DR30-second take

A standard coronary CT angiogram (CCTA, ~$400 to $450 self-pay) uses IV contrast dye to see both hardened calcium and the soft, non-calcified plaque that a calcium score of zero misses. Standard CCTA is the only heart CT strategy proven in randomized trials (SCOT-HEART 10-year follow-up) to reduce heart attacks by guiding earlier preventive therapy. Cleerly is an optional $1,500 AI software overlay on that same CCTA file that measures plaque volume in cubic millimeters (mm³). While Cleerly has strong observational risk-prediction data, zero completed randomized trials show that AI plaque staging improves survival or prevents more heart attacks than a standard CAD-RADS 2.0 CCTA paired with driving ApoB below 60 mg/dL.

TL;DR - The Plain-Language Summary

  • What a CCTA sees that a Calcium Score misses: A $100 to $150 coronary calcium score (CAC) only sees old, calcified bone-like scars. Across 37,808 asymptomatic adults with a calcium score of zero (CAC = 0), 10% to 16% still carry soft, non-calcified plaque on a contrast CCTA (24.2% when Lp(a) is high, and 42% to 58% of plaques in adults under 40).
  • The $450 Standard CCTA vs. the $2,000 Cleerly AI Add-On: Both use the same CT scanner, the same IV contrast trip, and the same radiation dose (0.5 to 2.5 mSv on modern dual-source scanners). A standard radiologist read (CAD-RADS 2.0, $400 to $450) tells us whether soft plaque or high-risk plaque features exist today. Adding the Cleerly AI software layer ($1,800 to $2,200 total) outputs a plaque volume in cubic millimeters (mm³).
  • The clinical evidence gap: Standard CCTA is the only modality here proven in a 10-year randomized clinical trial (SCOT-HEART, n = 4,146) to cut heart attacks by 28% (HR 0.72) through earlier statin and lipid therapy. By contrast, both the 2025 American College of Cardiology (ACC) Scientific Statement and 2026 QCI Consensus note that zero completed randomized trials show AI plaque staging improves clinical outcomes over standard CAD-RADS 2.0 CCTA plus lipid lowering (the first randomized trial, TRANSFORM, is still enrolling).
  • Your Monday-morning rule: If you want to know whether soft plaque is hiding behind a zero calcium score or borderline cholesterol today -> Then order the $400 to $450 standard-read CCTA first, and save the $1,500 Cleerly AI fee unless you plan to pay for a repeat scan in 2 to 3 years to track cubic-millimeter shrinkage.

Longevity clinics often present heart imaging as an all-or-nothing choice between a basic $100 calcium score and a $2,000+ Cleerly AI scan. Meanwhile, traditional primary care clinics rarely look at the coronary arteries at all until someone develops chest pain on a treadmill.

Both approaches leave patients with the wrong impression. If you want to see whether early, rupture-prone soft plaque has started building inside your heart arteries, you do not have to spend $2,000. The workhorse test that sees soft plaque is the standard coronary CT angiogram (CCTA), which costs roughly $400 to $450 self-pay at Philadelphia and South Jersey imaging centers. Cleerly (AI-QCT) is an optional post-processing software fee layered onto that same CT file after you leave the scanner.12

Heart Scans Compared: Calcium Score (CAC = 0) vs. Standard CCTA vs. AI Plaque Overlays

How testing works here

Dr. Ash orders this the same way he orders everything else, as part of primary care, so it is not something you can buy from us by itself. A number with nobody to read it against the rest of your picture is how most people end up with a result sitting in a portal and no idea what to do next.

What that looks like from your side is straightforward. The lab or imaging center bills you directly, at their price, with nothing added by us. Dr. Ash sends the order, reads the result next to your history and your other labs, and turns it into a plan you leave with. If there is something specific you want measured, that is a good thing to say up front.

Tell Dr. Ash what you want to find out

Why Does a Calcium Score of Zero (CAC = 0) Miss Soft Plaque in Younger Adults?

A calcium score of zero (CAC = 0) misses 10% to 16% of asymptomatic adults who carry soft, non-calcified plaque - including 58% of obstructive plaques under age 40, 34% in your 40s, and 24.2% of adults with high Lp(a) (>= 125 nmol/L).

When cholesterol-carrying ApoB particles enter the inner wall of a coronary artery, the plaque they form starts out soft, lipid-rich, and non-calcified. It takes years of healing and scarring for the body to lay down calcium inside that plaque. Because a non-contrast calcium score only detects dense calcium crystals, early soft plaque is invisible to it.34

Four landmark imaging studies quantify how often CAC = 0 misses active disease:

  1. Pooled asymptomatic prevalence (10% to 16.2%): Across a meta-analysis of 14 studies and 37,808 asymptomatic adults with CAC = 0, 10% carried non-calcified soft plaque (95% CI 6% to 13%), with men carrying more than triple the odds of women (OR 3.22).3 In the Swedish SCAPIS cohort (n = 25,182, ages 50 to 64), 5.5% of CAC = 0 adults had plaque on CCTA (7.3% of men, 4.3% of women, and 9.2% of intermediate-risk adults).5 In the U.S. Miami Heart Study (n = 2,359 asymptomatic adults aged 40 to 65), 16.2% of participants with CAC = 0 had coronary plaque, and 91% of those plaques (14.8% overall) were purely non-calcified soft plaque.6
  2. The under-55 age trap (Mortensen et al., JAMA Cardiology 2022 & NEJM 2026): Because younger arteries have not had decades to calcify, a zero score is least reliable under age 55. In 23,759 symptomatic patients (JAMA Cardiology), the share of obstructive coronary blockages (>= 50% narrowing) that had a CAC = 0 score was 58% under age 40, 34% at ages 40 to 49, 18% at ages 50 to 59, and only 5% at age 70 and older.7 In the 2026 New England Journal of Medicine population study (Bundgaard et al.), 41.8% of men and 48.4% of women aged 30 to 39 who had coronary plaque on CCTA had a calcium score of zero.8
  3. High Lp(a), high LDL-C / ApoB, and family history: In Miami Heart, statin-naive adults with CAC = 0 and high Lp(a) (>= 125 nmol/L) had a 24.2% prevalence of hidden plaque compared to 14.2% when Lp(a) was normal (p < 0.001), along with nearly quadruple the odds of carrying 2 or more high-risk plaque features (OR 3.94).9 Similarly, as LDL-C rose from < 70 mg/dL to >= 190 mg/dL in CAC = 0 adults, hidden plaque doubled from 13.2% to 28.2% in Miami Heart and from 11.4% to 22.8% in the Western Denmark Heart Registry (n = 23,777), where higher LDL-C drove a 39% jump in soft plaque odds per 1 mmol/L (38.7 mg/dL) in adults 45 and under (aOR 1.39, event aHR 1.37).1011
  4. Prognostic danger when soft plaque narrows the vessel or shows high-risk features: In the CONFIRM registry (n = 10,037), patients with CAC = 0 who had obstructive soft plaque (>= 50% narrowing) had a 5.7-fold higher risk of cardiac events (3.9% vs 0.8%, HR 5.7), and in the ICONIC acute coronary syndrome study, 23% of patients who suffered a heart attack or unstable angina had CAC = 0.1213 Across 13,977 patients (Nerlekar et al.), specific high-risk soft plaque features visible on a standard CCTA multiplied event risk: positive outward remodeling (HR 2.58), low-attenuation lipid-core plaque (< 30 HU, HR 2.95), napkin-ring sign (HR 5.06), and 2 or more high-risk features (HR 9.17).14

For that reason, the 2026 ACC/AHA Dyslipidemia Guideline states that a calcium score of zero (CAC = 0) should not be used to hold off on statin therapy in adults with a strong family history of premature heart disease (MESA HR 1.73), diabetes (30% plaque rate in Miami Heart and only a 3-year CAC = 0 warranty), current smoking (MESA HR 2.19), or familial hypercholesterolemia (LDL-C >= 190 mg/dL).1516

Does Cleerly AI Improve Heart Outcomes Over a Standard $450 CCTA?

No completed randomized trial shows that Cleerly AI plaque staging prevents more heart attacks than a standard radiologist-read CCTA (CAD-RADS 2.0) paired with intensive lipid lowering - while standard CCTA is proven over 10 years (SCOT-HEART) to cut heart attacks by 28%.

To spend your healthcare dollars wisely, it helps to separate two questions: 1) Does looking inside the arteries with a CCTA prevent heart attacks? and 2) Does paying an extra $1,500 for AI software on top of that CCTA improve outcomes further?

1. Standard CCTA has 10-year randomized trial proof (SCOT-HEART)

In the landmark SCOT-HEART randomized trial (n = 4,146 patients with stable chest pain), adding a standard-read CCTA to usual care lowered coronary death or nonfatal heart attack by 41% at 5 years (2.3% vs 3.9%, HR 0.59, p = 0.004).17 In the 10-year follow-up published in The Lancet (2025), the protection held strong: coronary death or nonfatal heart attack remained 21% lower (6.6% vs 8.2%, HR 0.79, p = 0.044) and nonfatal heart attacks were 28% lower (HR 0.72, p = 0.017).18

How did SCOT-HEART prevent heart attacks? Rates of coronary stents and bypass surgery were identical between groups (HR 1.00).18 Seeing the non-calcified plaque on a standard CCTA prompted doctors and patients to start preventive statin and antiplatelet therapy early instead of waiting for a blockage to rupture. Similarly, in the 10.6-year follow-up of the PROMISE randomized trial (n = 10,003, JAMA Cardiology 2025), any plaque abnormality on CCTA predicted long-term mortality (adjusted HR 1.99 to 3.44) far more sensitively than mild or moderate stress-test abnormalities.19

2. What AI quantitative plaque overlays (Cleerly / AI-QCT) add - and where the evidence stops

Software platforms like Cleerly (AI-QCT) and HeartFlow Plaque run automated voxel-by-voxel segmentation on the raw CCTA file to calculate total plaque volume (TPV in mm³), percent atheroma volume (PAV), non-calcified plaque volume (NCPV), and low-attenuation necrotic-core volume (< 30 HU).12

Across observational registries and post-hoc trial re-reads, higher AI plaque volumes consistently track with higher event rates, though the incremental boost over a standard CAD-RADS 2.0 radiologist read is modest in most cohorts:

Fishtown Medicine

A 90-minute conversation with Dr. Ash. A written plan you can follow.

Start your intake
Study / CohortSample SizeAI Quantitative Plaque Finding (Verbatim)Incremental Discrimination vs. Standard Read (Gist)
CONFIRM2 Registry (2026)201,916AI-quantified non-calcified plaque volume predicted death or MI in non-obstructive diseaseModest AUC gain over CAD-RADS 2.0 (0.81 vs 0.79; NRI 0.47) and over CAC (0.79 vs 0.70)
10-Year Staging Cohort (Nurmohamed 2024)21536Stage 3 non-calcified plaque (> 7.5% PAV) carried adjusted HR 4.37 for 10-year eventsAUC improved from 0.78 (CAD-RADS 2.0) to 0.82 (p = 0.032; NRI 0.09)
ISCHEMIA Trial Post-Hoc (2024)223,711Total plaque volume (TPV) predicted CV death or MI (adjusted HR 1.56 per IQR, p = 0.001)Small AUC change (0.65 vs 0.61) over clinical and anatomic variables
SCOT-HEART Deep-Learning & LAP Substudies23241,611Low-attenuation plaque burden > 4% carried HR 4.65 for MI (~7x in non-obstructive plaque); TPV >= 238.5 mm³ carried HR 5.36Proves soft lipid-core burden drives heart attacks independent of percent narrowing
ADVANCE Registry (HeartFlow 2024)254,430Total plaque volume > 564 mm³ carried adjusted HR 1.52 (p = 0.013) beyond stenosis + FFRctAdds prognostic stratification in patients already undergoing functional flow modeling
CORE320 Multicenter Study (Negative)1381Quantitative plaque features did not improve prediction over standard CAC (AUC 0.64 vs 0.65)Shows AI volume does not outperform simpler scoring in every population

Both the 2025 ACC Scientific Statement on Quantitative Coronary Plaque Analysis (Chandrashekhar et al.) and the 2026 QCI Study Group Consensus (Nature Reviews Cardiology) emphasize a central boundary: while AI plaque software changes physician prescribing in > 50% of clinic visits (CERTAIN and DECIDE registries), there is currently zero randomized trial evidence showing that AI-staged treatment prevents more heart attacks than a standard CAD-RADS 2.0 CCTA paired with aggressive ApoB lowering.2232627 The first randomized outcomes trial testing AI plaque staging (TRANSFORM, NCT06112418) is still enrolling.12

What Is the Cost and Radiation Ladder for Heart Scans in Philadelphia?

A $400 to $450 standard-read CCTA delivers 0.5 to 2.5 mSv on a modern dual-source scanner and answers whether you have soft plaque today, while the $1,800 to $2,200 Cleerly add-on adds 0 mSv of extra radiation and is reserved for serial mm³ tracking.

When you compare cardiac imaging options in Greater Philadelphia and South Jersey (such as our preferred independent 3T/dual-source centers like Princeton Radiology in Newtown), four steps rest on the ladder:

Heart Imaging OptionTypical Self-Pay CostTypical vs. Best-Case Modern Radiation (mSv)What It Sees (Evaluative Boundary)When Fishtown Medicine Orders It
1. Carotid + Abdominal Aortic Ultrasound~$100 (or insurance-covered)0 mSv (sound waves only)Plaque in the neck or abdominal aorta; cannot see the coronary arteriesFast, zero-radiation check to see if atherosclerosis has started in surface vessels
2. Coronary Calcium Score (CAC)$100 to $1500.5 to 1.5 mSv (0.37 mSv with iterative reconstruction)28Hardened calcified scars only; misses 10% to 16% of soft plaque (58% under age 40)First-line triage in lower-risk, non-smoking adults over 50 without high Lp(a) or family history
3. Standard-Read CCTA (CAD-RADS 2.0)$400 to $4500.5 to 2.5 mSv on 3rd-gen dual-source CT (0.21 to 0.63 mSv high-pitch spiral when HR < 60 bpm)2930Soft non-calcified plaque, calcified plaque, high-risk plaque features, and stenosis; proven in SCOT-HEART RCTOur default high-value choice when ApoB or Lp(a) is high, family history is strong, or we need a tie-breaker on starting a statin
4. CCTA + Cleerly AI Overlay (AI-QCT)$1,800 to $2,200Same as underlying CCTA (+0 mSv from AI) - avoid bundling an unneeded separate CAC scan that doubles dose2Outputs precise plaque volumes in mm³ (LD-NCP, non-calcified, calcified) for serial comparisonReserved for patients who already know they want to pay for a repeat scan in 24 to 36 months to measure mm³ plaque regression

Two radiation tips that cut your dose in half

  1. Choose a modern 3rd-generation dual-source CT scanner and prep your heart rate below 60 bpm: In the 2026 JAMA worldwide radiation study (Einstein et al.), median CCTA dose across random global centers was 5.6 to 7.4 mSv, with 72% of the variation coming down to center protocol instead of patient size.31 On a modern 3rd-generation dual-source scanner using high-pitch spiral mode (Flash mode when resting heart rate is < 60 bpm) and deep-learning image reconstruction (Benz et al.), total radiation drops by 43% down to 0.21 to 1.5 mSv - roughly equal to a standard calcium score or a few months of natural background radiation.293032
  2. Do not let an AI protocol tack on a redundant non-contrast CAC scan if you only need the CCTA: Because Cleerly and other AI software run directly on the contrast CCTA images, the AI analysis itself adds 0 mSv of radiation.2 However, some imaging bundles automatically perform both a non-contrast CAC scan and a contrast CCTA back-to-back, which adds 0.5 to 1.5 mSv of extra radiation you do not need if the decision rests on soft plaque.2

Who Should Avoid a CCTA (or Use a Different Test)?

  • Severe kidney disease (eGFR < 30 mL/min) or severe iodine contrast allergy: Because CCTA requires intravenous iodine contrast dye, we use non-contrast calcium scoring, carotid ultrasound, or stress echocardiography instead.
  • Asymptomatic adults under age 35 without genetic risk: Unless you have familial hypercholesterolemia (LDL-C >= 190 mg/dL), extreme Lp(a), or a parent who had a heart attack in their 30s or 40s, we drive prevention from your ApoB and Lp(a) blood panel instead of radiating the chest in your 20s or early 30s.
  • Annual repeat scanners: Repeating a CCTA every 12 months adds unnecessary radiation and contrast exposure. Even in randomized plaque-regression trials (CAUGHT-CAD), meaningful differences in non-calcified plaque volume (5.6 vs 15.7 mm³ on atorvastatin 40 mg) are tracked over 24 to 36 months.233

Your Monday-Morning Heart Imaging Protocol (If -> Then Rules)

  1. If you are under 55, have high Lp(a) (>= 125 nmol/L), high ApoB, or a premature family history -> Then do not use a Calcium Score of 0 to talk yourself out of treatment. Under age 50, 34% to 58% of significant coronary plaques have CAC = 0, and the 2026 ACC/AHA guideline explicitly rules against deferring statins in high-risk family history, diabetes, smoking, or FH on the basis of zero calcium.715
  2. If you want to know whether soft plaque exists in your arteries today -> Then order a $400 to $450 standard-read CCTA (with CAD-RADS 2.0 grading) on a modern dual-source scanner. You get the only imaging test proven in randomized trials (SCOT-HEART) to cut heart attacks over 10 years, at one-fifth the price of an AI bundle.18
  3. If your CCTA shows any non-calcified soft plaque or high-risk plaque features -> Then drive ApoB below 60 mg/dL (or < 50 mg/dL if Lp(a) is high). Once plaque is visible inside the artery wall, the debate between lifestyle and medication is settled: we combine nutrition, exercise, and targeted lipid therapy (statins, ezetimibe, or PCSK9 inhibitors) to delipidate and stabilize the plaque.1833
  4. If you are booked for a CCTA -> Then prep your heart rate below 60 bpm the morning of the scan. Skip caffeine for 12 hours, fast for 4 hours, hold PDE5 inhibitors (sildenafil or tadalafil) for 48 hours, and take the prescribed morning oral beta-blocker (metoprolol) so the scanner can use its lowest-radiation (0.5 to 1.5 mSv), sharpest-image mode.2930

Tell Dr. Ash what's going on

A note on cost: any discount we negotiate on labs and imaging passes straight through to you, with no markup. Our affordable labs and imaging guide covers how the billing works.

Scientific References

  1. Cramer SHM, Danad I, Knaapen P, Nurmohamed NS, Choi AD. Innovations in artificial intelligence-guided atherosclerosis cardiovascular imaging: from detection to prognosis. Curr Atheroscler Rep. 2026;28(1):15. DOI
  2. Saiani R, Ballantyne CM. Coronary computed tomography and artificial intelligence-based plaque analysis. Curr Atheroscler Rep. 2026;28(1):19. DOI
  3. Sama C, Abdelhaleem A, Velu D, et al. Non-calcified plaque in asymptomatic patients with zero coronary artery calcium score: a systematic review and meta-analysis. J Cardiovasc Comput Tomogr. 2023;17(6):405-414. PubMed
  4. Slipczuk L, Blankstein R, Bucciarelli-Ducci C, et al. State of the art: evaluation and medical management of nonobstructive coronary artery disease in patients with chest pain: a scientific statement from the American Heart Association. Circulation. 2025;151(8):e650-e672. DOI
  5. Bergstrom G, Persson M, Adiels M, et al. Prevalence of subclinical coronary artery atherosclerosis in the general population (SCAPIS). Circulation. 2021;144(12):916-929. PubMed
  6. Nasir K, Cainzos-Achirica M, Valero-Elizondo J, et al. Coronary atherosclerosis in an asymptomatic U.S. population: Miami Heart Study at Baptist Health South Florida. JACC Cardiovasc Imaging. 2022;15(9):1604-1618. PubMed
  7. Mortensen MB, Gaur S, Frimmer A, et al. Association of age with the diagnostic value of coronary artery calcium score for ruling out coronary stenosis in symptomatic patients. JAMA Cardiol. 2022;7(1):36-44. DOI
  8. Bundgaard H, Garcia-Lunar I, Kofoed KF, et al. Prevalence of silent atherosclerosis across adult life. N Engl J Med. 2026. DOI
  9. Mszar R, Cainzos-Achirica M, Valero-Elizondo J, et al. Lipoprotein(a) and coronary plaque in asymptomatic individuals: the Miami Heart Study at Baptist Health South Florida. Circ Cardiovasc Imaging. 2024;17(7):e016152. PubMed
  10. Hagan K, Mszar R, Cainzos-Achirica M, et al. Low-density lipoprotein-cholesterol and subclinical coronary atherosclerosis in a middle-aged asymptomatic U.S. population: the Miami Heart Study. Atherosclerosis. 2024;397:118562. PubMed
  11. Andersen MH, Jensen JM, Kanstrup H, et al. Low-density lipoprotein cholesterol and cardiovascular risk in the absence of calcifications on computed tomography: the Western Denmark Heart Registry. Eur Heart J. 2025;46(34):3312-3322. PubMed
  12. Villines TC, Hulten EA, Shaw LJ, et al. Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography: results from the CONFIRM registry. J Am Coll Cardiol. 2011;58(24):2533-2540. PubMed
  13. Jonas RA, Nurmohamed NS, Crabtree TR, et al. CTA-derived plaque characteristics and risk of acute coronary syndrome in patients with coronary artery calcium score of zero: insights from the ICONIC trial. AJR Am J Roentgenol. 2025;224(6):e2432110. PubMed
  14. Nerlekar N, Ha FJ, Cheshire C, et al. Computed tomographic coronary angiography-derived plaque characteristics predict major adverse cardiovascular events: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2018;11(1):e006973. PubMed
  15. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia. Circulation. 2026. DOI
  16. Al Rifai M, Blaha MJ, Nambi V, et al. Determinants of incident atherosclerotic cardiovascular disease events among those with absent coronary artery calcium: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2022;145(4):259-267. PMC
  17. SCOT-HEART Investigators, Newby DE, Adamson PD, et al. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med. 2018;379(10):924-933. DOI
  18. Williams MC, Wereski R, Tuck C, et al. Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland. Lancet. 2025;405(10476):329-340. PubMed
  19. Douglas PS, Stebbins A, Foldyna B, et al. Survival after initial stress testing vs anatomic testing in suspected coronary artery disease: long-term follow-up of the PROMISE randomized clinical trial. JAMA Cardiol. 2025;10(10):1012-1021. DOI
  20. van Rosendael A, Nakanishi R, Bax JJ, et al. Prognostic value of AI-based quantitative coronary CTA vs human reader-based visual assessment: results from the CONFIRM2 registry. JACC Cardiovasc Imaging. 2026;19(2):188-200. PubMed
  21. Nurmohamed NS, Bom MJ, Jukema RA, et al. AI-guided quantitative plaque staging predicts long-term cardiovascular outcomes in patients at risk for atherosclerotic CVD. JACC Cardiovasc Imaging. 2024;17(3):269-280. PubMed
  22. Nurmohamed NS, Min JK, Anthopolos R, et al. Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial. Eur Heart J. 2024;45(36):3735-3747. PMC
  23. Schulze K, Stantien AM, Williams MC, et al. Coronary CT angiography evaluation with artificial intelligence for individualized medical treatment of atherosclerosis: a consensus statement from the QCI Study Group. Nat Rev Cardiol. 2026;23(2):112-128. DOI
  24. Williams MC, Kwiecinski J, Doris M, et al. Low-attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction: results from the multicenter SCOT-HEART trial. Circulation. 2020;141(18):1452-1462. PubMed
  25. Dundas J, Leipsic J, Fairbairn T, et al. Interaction of AI-enabled quantitative coronary plaque volumes on coronary CT angiography, FFRCT, and clinical outcomes: a retrospective analysis of the ADVANCE registry. Circ Cardiovasc Imaging. 2024;17(3):e016140. PubMed
  26. Nurmohamed NS, Cole JH, Budoff MJ, et al. Impact of atherosclerosis imaging-quantitative computed tomography on diagnostic certainty, downstream testing, coronary revascularization, and medical therapy: the CERTAIN study. Eur Heart J Cardiovasc Imaging. 2024;25(6):857-866. PubMed
  27. Rinehart S, Blankstein R, McCarthy CP, et al. Guiding preventive care strategies for patients with atherosclerotic plaque on coronary CTA: primary outcomes of the DECIDE registry. JACC Cardiovasc Imaging. 2026;19(4):412-424. PubMed
  28. Patel AA, Fine J, Naghavi M, Budoff MJ. Radiation exposure and coronary artery calcium scans in the Society for Heart Attack Prevention and Eradication cohort. Int J Cardiovasc Imaging. 2019;35(1):179-183. DOI
  29. Kosmala A, Petritsch B, Weng AM, Bley TA, Gassenmaier T. Radiation dose of coronary CT angiography with a third-generation dual-source CT in a true-world patient population. Eur Radiol. 2019;29(8):4341-4348. PubMed
  30. Stehli J, Fuchs TA, Bull S, et al. Accuracy of coronary CT angiography using a submillisievert fraction of radiation exposure: comparison with invasive coronary angiography. J Am Coll Cardiol. 2014;64(8):772-780. PubMed
  31. Einstein AJ, Williams MC, Weir-McCall JR, et al. Worldwide radiation dose in coronary artery disease diagnostic imaging. JAMA. 2026;335(11):980-992. DOI
  32. Benz DC, Ersozlu S, Mojon FLA, et al. Radiation dose reduction with deep-learning image reconstruction for coronary computed tomography angiography. Eur Radiol. 2022;32(4):2620-2628. PubMed
  33. Nerlekar N, Vasanthakumar SA, Whitmore K, et al. Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: a randomized clinical trial (CAUGHT-CAD). JAMA. 2025;333(12):1045-1054. DOI

Dr. Ash is a board-certified internal medicine physician at Fishtown Medicine in Philadelphia. He practices Medicine 3.0 preventive cardiology so your heart lasts as long as your ambition.

Ashvin Vijayakumar MD (Dr. Ash)

Fishtown Medicine | Diagnostics

2418 E York St, Philadelphia, PA 19125·(267) 360-7927·hello@fishtownmedicine.com·HSA/FSA Eligible

Start Your Intake
Medical Disclaimer: This resource provides clinical context for educational purposes. In the world of Precision Medicine, there is no "one size fits all", the right plan must be matched to your unique lab work, physiology, and goals. Consult Dr. Ash to determine if this approach is right for you, particularly if you have chronic health conditions or are taking prescription medications.

Frequently Asked Questions

Common Questions

Both start with the same medical test: a coronary CT angiogram (CCTA) using intravenous iodine contrast dye on a high-speed CT scanner. A standard-read CCTA (~$400 to $450 self-pay in Philadelphia) is interpreted by a cardiovascular radiologist or cardiologist using the CAD-RADS 2.0 grading system, which identifies calcified plaque, non-calcified soft plaque, vessel narrowing (stenosis), and high-risk plaque features. A Cleerly CTA (~$1,800 to $2,200 total) sends that same scan file to Cleerly's artificial intelligence software (AI-QCT), which outputs precise plaque volumes in cubic millimeters (mm³). If your question is whether you have soft plaque today, the $450 standard read answers it; Cleerly is only needed if you want a cubic-millimeter baseline to compare against another scan 2 to 3 years later.
Yes. Across 14 studies of 37,808 asymptomatic adults with a calcium score of zero (CAC = 0), 10% carried non-calcified soft plaque (16.2% in the U.S. Miami Heart Study, and 24.2% among CAC = 0 adults with high Lp(a) >= 125 nmol/L). Because early plaque starts soft and takes years to calcify, CAC = 0 is least reliable in younger adults: in a *JAMA Cardiology* study of 23,759 patients, 58% of obstructive coronary blockages under age 40 and 34% at ages 40 to 49 had a calcium score of zero.
Not yet. Standard CCTA has 10-year randomized clinical trial proof from the SCOT-HEART trial (n = 4,146, *The Lancet* 2025), showing a 28% reduction in nonfatal heart attacks (HR 0.72) driven by earlier preventive medication. By contrast, as the 2025 ACC Scientific Statement and 2026 QCI Consensus highlight, Cleerly and other AI-QCT platforms currently rest on observational registries (CONFIRM2, CERTAIN, DECIDE). The first randomized trial testing whether AI plaque staging improves cardiovascular event outcomes (TRANSFORM, NCT06112418) is still enrolling.
The Cleerly AI software itself adds 0 mSv of radiation because it is computer post-processing on your CCTA image file. On a modern 3rd-generation dual-source CT scanner with a resting heart rate slowed below 60 bpm and deep-learning image reconstruction, a CCTA delivers roughly 0.5 to 2.5 mSv (and as low as 0.21 to 0.8 mSv in high-pitch spiral mode), which is less than one year of natural background radiation (~3 mSv). Older scanners or centers using retrospective protocols can deliver 5 to 7+ mSv, which is why Fishtown Medicine routes patients to modern dual-source cardiac CT centers.
Yes. While calcified plaque is permanent scar tissue that rarely shrinks (and often gets denser as plaque heals), lipid-rich non-calcified soft plaque can shrink and stabilize when ApoB is driven below 50 to 60 mg/dL using statins, ezetimibe, or PCSK9 inhibitors (Repatha or Praluent). In the randomized CAUGHT-CAD trial (2025), atorvastatin 40 mg significantly slowed non-calcified plaque progression (5.6 vs 15.7 mm³).

Deep-Dive Questions

On a contrast CCTA (graded under CAD-RADS 2.0), radiologists and AI software look for four structural markers of an inflamed, thin-capped vulnerable plaque:
CAD-RADS 2.0 is the standardized reporting system used by cardiac radiologists on a $400 to $450 CCTA. It pairs a stenosis grade (0 = no plaque, 1 = 1-24% minimal, 2 = 25-49% mild, 3 = 50-69% moderate, 4 = 70-99% severe, 5 = 100% occluded) with an overall plaque burden grade (P1 mild to P4 extensive) and a modifier for high-risk plaque features (HRP). In the CONFIRM2 (n = 1,916) and Nurmohamed 10-year (n = 536) studies, CAD-RADS 2.0 already achieved strong event discrimination (AUC 0.78 to 0.79), with AI-QCT nudging the C-statistic to 0.81 to 0.82.
Cleerly measures plaque anatomy and composition inside the artery wall (how many cubic millimeters of calcified vs non-calcified vs low-attenuation plaque exist), which is most useful in early preventive care when narrowing is mild (< 50%). HeartFlow (FFR-CT) models <strong>fluid dynamics and blood flow pressure drops across a moderate-to-severe narrowing (50% to 90% stenosis) to decide whether a patient with chest pain needs a catheterization or stent, though HeartFlow also now offers a quantitative plaque module (ADVANCE registry, n = 4,430).
Many concierge and longevity clinics bundle $2,000+ scans into high-margin diagnostic packages. At Fishtown Medicine, our only revenue is our transparent membership or package fee. Whether we order a $100 carotid/aortic ultrasound, a $125 calcium score, a $425 standard-read CCTA, or a Cleerly AI overlay, you pay the imaging center's direct self-pay or insurance rate with zero practice markup. Our affordable labs and imaging guide explains how we route every order.

Ready when you are

Start your intake

The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.

Related Intelligence

Preventive Cardiology Philadelphia | ApoB & Lp(a) Testing

Preventive Cardiology Philadelphia | ApoB & Lp(a) Testing

Standard cholesterol panels miss most heart attacks. See how a Philadelphia preventive cardiology approach uses ApoB, Lp(a), and modern imaging to catch risk early.

Read Deep Dive
ApoB vs LDL: Why Your "Normal" Cholesterol Score Might Be Misleading

ApoB vs LDL: Why Your "Normal" Cholesterol Score Might Be Misleading

A guide to ApoB vs LDL and why a normal cholesterol report can still hide serious heart risk. From a Medicine 3.0 practice in Philadelphia.

Read Deep Dive
Early Cancer Detection and Whole Body MRI Philadelphia | Medicine 3.0

Early Cancer Detection and Whole Body MRI Philadelphia | Medicine 3.0

Go beyond standard cancer screening. A Philadelphia primary care practice using liquid biopsies and whole-body MRI to find disease earlier.

Read Deep Dive

New patients

Talk it through with Dr. Ash.

If anything you read here raised a question, share it in your own words. Dr. Ash reads every intake personally, and you can text or email us anytime.

HSA/FSA eligible
No initiation or cancellation fees
No copays
Tell Dr. Ash what’s going on →
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
2418 E York St, Philadelphia, PA 19125(267) 360-7927Primary care in PhiladelphiaHome visits in Greater PhiladelphiaPricing & MembershipGER·O·SPAN: our clinical frameworkDigital Health LiteracyClinical Evidence & Research

Serving Fishtown · Northern Liberties · East Kensington · Olde Richmond · Port Richmond · Old City · Callowhill · Poplar · Center City · Center City West · Art Museum · Bella Vista · Chestnut Hill · Fairmount · Fitler Square · Graduate Hospital · Logan Square · Manayunk · Queen Village · Rittenhouse · Roxborough · Society Hill · Southwark · Bryn Mawr, PA · Gladwyne, PA · Villanova, PA · Wayne, PA · Cherry Hill, NJ · Haddonfield, NJ · Medford, NJ · Moorestown, NJ · Voorhees, NJ

Explore by topic

Women’s Health
  • Perimenopause
  • Menopause 3.0
  • PCOS
  • Fertility
Men’s Health
  • Testosterone (TRT)
  • Sleep Apnea & Low T
  • Andropause
  • Low Libido
Metabolic
  • Medical Weight Loss
  • Ozempic vs Metformin
  • Fasting Protocols
  • Visceral Fat
Cardiovascular
  • apoB & Heart Health
  • apoB vs LDL
  • Lp(a) Cholesterol
  • ED & Heart Risk
Longevity + Performance
  • Healthspan vs Lifespan
  • Biological Age
  • VO2 Max
  • Zone 2 Training
Supplements
  • Magnesium
  • Creatine
  • Omega-3
  • Foundational Stack
  • Supplement Guides
Care in Philadelphia +
Direct Primary Care in Philadelphia, PAConcierge Medicine in Philadelphia, PAConcierge vs DPC in Philadelphia, PALongevity Medicine in Philadelphia, PAPreventive Care in Philadelphia, PAExecutive Physical in Philadelphia, PAAnnual Physical in Philadelphia, PAHealthspan Optimization in Philadelphia, PAFunctional Medicine in Philadelphia, PASame-Day Sick Visits in Philadelphia, PATestosterone Replacement Therapy in Philadelphia, PAPerimenopause Care in Philadelphia, PAMenopause Care in Philadelphia, PAThyroid Treatment in Philadelphia, PAPCOS Care in Philadelphia, PAGLP-1 Weight Loss in Philadelphia, PAMetabolic Health in Philadelphia, PAHormone Optimization in Philadelphia, PAAdvanced Lipid Testing in Philadelphia, PAVO2 Max Testing in Philadelphia, PADEXA Scan in Philadelphia, PACGM in Philadelphia, PALong COVID Care in Philadelphia, PAChronic Fatigue Treatment in Philadelphia, PAPOTS Treatment in Philadelphia, PAMCAS Treatment in Philadelphia, PALyme Disease Care in Philadelphia, PABrain Fog Treatment in Philadelphia, PASleep Disorders Treatment in Philadelphia, PAStrep Throat Treatment in Philadelphia, PAUTI Treatment in Philadelphia, PASinus Infection Treatment in Philadelphia, PASTI Testing in Philadelphia, PATravel Medicine in Philadelphia, PAPre-Op Clearance in Philadelphia, PASports Club Medicine in Philadelphia, PA

Made it this far? You’re already most of the way there. let’s get started → Dr. Ash reads every word personally.

Content is for educational purposes only and does not constitute medical advice.

TermsPrivacyScope of PracticeClinical IndependenceCare NetworkResearch & Monographs